Pipeline Flex embolisation device with Shield Technology for the treatment of complex

efficacy of Pipeline with other interventions was very limited. This made evaluation difficult. The committee recognised the difficulties in conducting comparative studies, particularly randomised controlled trials, for large and giant complex intracranial aneurysms. 3.22 The committee noted that both new studies and an extension of the PUFS study are in progress. 3.23 The committee considered that data collection using a register would be an important practical way of developing evidence to guide future practice, in addition to the ongoing studies. 4 NHS considerations System impact 4.1 No secondary treatments were required at 1-year follow-up among patients in the PUFS study (FDA 2011). Need for retreatment was not reported in the PITA study (Nelson et al. 2011). Need for retreatment was not reported in the other 14 studies included in the external assessment centre's assessment report. Committee considerations 4.2 The committee noted that little evidence was available on the need for retreatment following treatment with Pipeline. 4.3 The committee recognised that there are a small number of patients for whom Pipeline offers the only possible means of treatment (an estimated 60 patients per year in the UK). For these patients the potential benefits offered by Pipeline are important, because they are
